|
|
|
| Effect of Nicorandil Combined with Levosimendan on Serum BNP, CRP and cTnI Levels in Patients with Ischemic Cardiomyopathy and Heart Failure |
| ZHANG Wei, LIU Yong-jun |
| Xi'an Fengcheng Hospital,Fengcheng Shaanxi 710000 |
|
|
|
|
Abstract 【Objective】 To investigate the effect of Nicorandil combined with Levosimendan on serum brain natriuretic peptide (BNP), C-reactive protein (CRP) and troponin I (cTnI) levels in patients with ischemic cardiomyopathy and heart failure. 【Methods】The clinical data of 150 patients with ischemic cardiomyopathy with heart failure treated in the Xi'an Fengcheng Hospital were selected and divided into Nicorandil group (group A), Levosimendan group (group B) and Nicorandil combined with Levosimendan group (Group C), with 50 cases in each group. The levels of serum BNP, CRP, cTnI, clinical efficacy and cardiac function [left ventricular end systolic diameter (LVESD), left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), 6 min walking distance] were compared among the three groups after treatment. 【Results】Compared with the group A and the group B, the levels of serum BNP, CRP and cTnI in the group C were significantly lower (P<0.05); There was no significant difference in the levels of serum BNP, CRP and cTnI between the group A and the group B (P>0.05). Compared with the group A and the group B, the group C had significantly lower LVEDD and LVESD, and significantly higher LVEF and 6-min walking distance (P<0.05); There was no significant difference in LVEDD, LVESD, LVEF and 6-min walking distance between the group A and the group B (P>0.05). The total effective rate of the group C was significantly higher than that of the group A and the group B, and the difference was statistically significant (P<0.05). 【Conclusion】 Nicorandil combined with Levosimendan has a good clinical effect in the treatment of ischemic cardiomyopathy with heart failure, which can significantly reduce the levels of serum BNP, CRP and cTnI, and better improve the cardiac function of patients, which is worthy of clinical reference.
|
|
Received: 22 December 2021
|
|
|
|
|
|
[1] 李延辉,陈瑶,黄莺,等. 三种药物联合治疗老年慢性缺血性心肌病心力衰竭患者室性心律失常的疗效[J].中国医药指南,2020,18(10):51-52.
[2] 张静. 尼可地尔治疗微血管性心绞痛的效果[J].中国民康医学,2020,32(3):37-39.
[3] 张伟华,邱伟林,李志龙. 左西孟旦治疗老年慢性心力衰竭的临床效果[J].中国当代医药,2020,27(10):46-49.
[4] 齐蕊. 冻干重组人脑利钠肽对老年缺血性心肌病心力衰竭患者血清超敏C反应蛋白与胱抑素C水平的影响[J].中国药物经济学,2020,15(1):111-113.
[5] 崔义.尼可地尔治疗慢性缺血性心肌病患者心力衰竭的临床疗效观察[J].中国医药指南,2018,16(11):118-119.
[6] 赵娟,金晶,吕学祥. 曲美他嗪在缺血性心肌病心力衰竭治疗中临床疗效观察[J].中国社区医师,2020,36(7):29-30.
[7] 王晓玉,江玲,陈日锦.曲美他嗪在缺血性心肌病心力衰竭治疗中的效果[J].吉林医学,2021,42(12):2851-2853.
[8] 康婧,宗莉,张正华.左西孟旦治疗慢性心力衰竭的效果[J].临床医学,2022,42(4):107-109.
[9] 周伟.左西孟旦治疗失代偿性心力衰竭的临床疗效[J].临床合理用药杂志,2022,15(11):52-54.
[10] 杨彦立.尼可地尔联合曲美他嗪治疗缺血性心肌病合并心力衰竭疗效观察[J].现代中西医结合杂志,2018,27(7):733-736.
[11] 郝建慧,高雅恒,岳磊.左西孟旦联合尼可地尔治疗老年缺血性心肌病心力衰竭患者的临床疗效和安全性[J].中国处方药,2021,19(10):128-129.
[12] 姚影. 探讨联检血浆B钠尿肽(BNP)、肌钙蛋白I(cTnI)和C反应蛋白(CRP)水平对慢性心力衰竭(CHF)患者疗效观察及预后评估的临床意义[J].首都医药,2020,27(9):115-116.
|
|
|
|
2022, Vol. 39 
